PCP
VYNE icon

Proficio Capital Partners’s VYNE Therapeutics VYNE Stock Holding History

Proficio Capital Partners’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1
Closed – – 1518
2019
Q2 		$0 Hold
1
– – ﹤0.01% 2094
2019
Q1 		$1K Buy
+1
New +$480 ﹤0.01% 1609

Other funds holding VYNE

First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Proficio Capital Partners's VYNE Position: Q3 2019 in Review

Proficio Capital Partners sold out of VYNE Therapeutics (VYNE) in Q3 2019, closing a stake of 1 share.

Proficio Capital Partners first reported a position in VYNE in Q1 2019 and held it in 2 quarters. The position peaked at $1K in Q1 2019. 55 funds tracked by Wall St. Rank hold VYNE as of Q3 2019.

  • Proficio Capital Partners reported no remaining VYNE Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 1 VYNE Therapeutics share in Q3 2019.
  • Proficio Capital Partners first reported a position in VYNE Therapeutics in Q1 2019 and held it in 2 quarters.
  • Proficio Capital Partners's VYNE Therapeutics position peaked at $1K in Q1 2019.
  • 55 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.